Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
7
×
new york top stories
boston blog main
boston top stories
clinical trials
new york blog main
national
san diego blog main
san diego top stories
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
gene therapy
novartis
pfizer
roche
spark therapeutics
abbvie
alnylam pharmaceuticals
amgen
amicus therapeutics
biogen
cancer
What
drug
7
×
patients
7
×
fda
approved
bio
new
roundup
disease
friday
help
market
medicine
pfizer
sets
therapy
acorda
acquisitions
advantages
ago
akcea
albert
alnylam
amyloidosis
aren’t
atrophy
attr
available
bar
battle
biggest
bourla
brings
cancer
ceo
company
cope
crispr
daily
debilitating
developers
Language
unset
unknown
Current search:
patients
×
drug
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More